Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Centrymed
company
About
Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform.
Highlights
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Health Care,Health Diagnostics,Medical Device
- Founded date
- Jan 1, 2017
- Operating Status
- Active
Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform. The company's independent intellectual property rights have solved the problems of drug drugability and toxic and side effects of antibody drugs.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
Centrymed has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Feb 9, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 9, 2022 | Series A | — | 7 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
7
Centrymed is funded by 7 investors.
Taikun Capital
and Binjiang District Government Fund Hang Gao Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
|
— | Series A |
|
|
— | Series A |
Yxassets.com
|
— | Series A |
|
|
— | Series A |
HongXin Venture Capital
|
— | Series A |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
